

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

_____)	
GENENTECH, INC)	
)	
Plaintiff,)	
)	C.A. No. 18-924-CFC
v.)	
)	
AMGEN, INC.,)	
)	
Defendant.)	
_____)	

**STIPULATION AND [PROPOSED] ORDER OF DISMISSAL
WITH RESPECT TO CERTAIN ASSERTED PATENTS**

WHEREAS Plaintiff Genentech, Inc. filed a Third Amended Complaint in this case on September 4, 2019, which asserts infringement of nine patents in connection with Defendant Amgen Inc. seeking FDA approval for ABP 980 as a trastuzumab biosimilar and marketing that biosimilar under the trade name Kanjinti (D.I. 347);

WHEREAS Genentech’s Third Amended Complaint includes claims for infringement of U.S. Patent Nos. 7,993,834, 8,076,066, and 8,440,402;

WHEREAS the Parties desire to streamline the issues in this case for trial;

NOW THEREFORE, it is hereby stipulated and agreed by the Parties, subject to the approval of the Court, that:

1. All claims for infringement of U.S. Patent Nos. 7,993,834, 8,076,066, and 8,440,402 (the “Dismissed Patents”) and (Counts VI, VII, and VIII of the Third Amended Complaint (D.I. 347)) are dismissed with prejudice;

2. All counterclaims for non-infringement, invalidity, and/or unenforceability of the Dismissed Patents are dismissed without prejudice to Amgen's ability to raise such claims in a later action; and

3. Each Party shall bear its own costs, expenses, and attorneys' fees associated with this action with respect to the Dismissed Patents.

This stipulation does not affect the parties' claims, counterclaims, or defenses with respect to the remaining patents-in-suit and shall not be admissible at trial in this case for any purpose with respect to the remaining patents-in-suit. This stipulation is for purposes of this case only and does not extend to litigation involving any other product between the parties. Neither party shall use this stipulation for any purpose in litigation between the parties relating to other products.

Dated: September 20, 2019

/s/ Alexandra M. Joyce

Michael P. Kelly (#2295)
Daniel M. Silver (#4758)
Alexandra M. Joyce (#6423)
MCCARTER & ENGLISH, LLP
Renaissance Centre
405 N. King Street, 8th Floor
Wilmington, DE 19801
(302) 984-6300
mkelly@mccarter.com
dsilver@mccarter.com
ajoyce@mccarter.com

OF COUNSEL:

William F. Lee
Lisa J. Pirozzolo
Emily R. Whelan
Kevin S. Prussia
Andrew J. Danford
WILMER CUTLER PICKERING
HALE AND DORR LLP
60 State Street
Boston, MA 02109
(627) 526-6000
william.lee@wilmerhale.com
lisa.pirozzolo@wilmerhale.com
emily.whelan@wilmerhale.com
kevin.prussia@wilmerhale.com
andrew.danford@wilmerhale.com

Robert J. Gunther Jr.
WILMER CUTLER PICKERING
HALE AND DORR LLP
7 World Trade Center
250 Greenwich Street
New York, NY 10007
(212) 230-8800
robert.gunther@wilmerhale.com

/s/ Neal C. Belgam

Neal C. Belgam (#2721)
Eve H. Ormerod (#5369)
Jennifer M. Rutter (#6200)
SMITH KATZENSTEIN & JENKINS LLP
1000 West Street, Suite 1501
Wilmington, DE 19801
(302) 652-8400
nbelgam@skjlaw.com
eormerod@skjlaw.com
jrutter@skjlaw.com

OF COUNSEL:

Michelle Rhyu
Susan Krumplitsch
Daniel Knauss
COOLEY, LLP
3175 Hanover Street
Palo Alto, CA 94304-1130
(650) 843-5287
skrumplitsch@cooley.com
mrhyu@cooley.com
dknauss@cooley.com

Orion Armon
COOLEY, LLP
380 Interlocken Crescent, Suite 900
Broomfield, CO 80021-8023
(720) 566-4119
oarmon@cooley.com

Eamonn Gardner
COOLEY, LLP
4401 Eastgate Mall
San Diego, CA 92121-1909
(858) 550-6086
egardner@cooley.com

Daralyn J. Durie
Adam R. Brausa
DURIE TANGRI LLP
217 Leidesdorff St.
San Francisco, CA 94111
(415) 362-6666
ddurie@durietangri.com
abrausa@durietangri.com

*Attorneys for Plaintiff
Genentech, Inc.*

Nancy Gettel
Thomas Lavery, IV
AMGEN, INC.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
P 805-447-1000
ngettel@amgen.com
tlavery@amgen.com

Attorneys for Defendant Amgen, Inc.

SO ORDERED this _____ day of _____, 2019.

United States District Judge